Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics

Category: Markets

Published: 2026-06-22T14:23:03.000Z

AbbVie announced its agreement to acquire Apogee Therapeutics for approximately $10.9 billion. This acquisition is not a new strategic direction for AbbVie but rather a move to strengthen its existing immunology portfolio, which has been central to the drugmaker's reputation.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.